Stifel Maintains Buy on Dyne Therapeutics, Raises Price Target to $66
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis maintains a Buy rating on Dyne Therapeutics (NASDAQ:DYN) and raises the price target from $41 to $66.
August 16, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Paul Matteis maintains a Buy rating on Dyne Therapeutics and raises the price target from $41 to $66.
The Buy rating and significant increase in the price target from $41 to $66 by a reputable analyst is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100